Press-release for stocks related to vaccine

Prices are updated after-hours

tags : Vaccine crawled time : 20:00

save search

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
Published: 2023-10-04 (Crawled : 20:00) - globenewswire.com
GRTS | $0.7414 -0.31% -0.31% 1.5M

Health Technology

| -69.8% | O: -2.45% H: 6.9% C: 0.84%
covid-19 candidate vaccine

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Published: 2023-09-27 (Crawled : 20:00) - globenewswire.com
GRTS | $0.7414 -0.31% -0.31% 1.5M

Health Technology

| -37.82% | O: 21.85% H: 11.03% C: 7.59%
covid-19 candidate vaccine contract study

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -25.78% | O: -0.03% H: 0.18% C: -0.88%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -14.89% | O: 1.65% H: 0.0% C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M

Health Technology

| -28.27% | O: -0.49% H: 0.2% C: -1.33%
covid-19 fda vaccine approval

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M

Health Technology

| -3.9% | O: -0.78% H: 0.42% C: -0.94%
covid-19 fda vaccine approval

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
Published: 2023-09-06 (Crawled : 20:00) - globenewswire.com
VXRT | News | $0.7652 -9.15% -10.08% 1.9M

Health Technology

| 8.75% | O: -1.25% H: 1.27% C: -6.84%
candidate vaccine norovirus topline study phase 2

Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
Published: 2023-08-08 (Crawled : 20:00) - globenewswire.com
ICVX | $15.31 -0.65% 9.3M

| 88.34% | O: 0.0% H: 6.26% C: 2.45%
ivx-121 candidate vaccine durability positive rsv potential

Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting
Published: 2023-04-17 (Crawled : 20:00) - biospace.com/
GRTS | $0.7414 -0.31% -0.31% 1.5M

Health Technology

| -75.58% | O: 1.98% H: 4.85% C: -7.77%
vaccine cancer meeting

Tonix Pharmaceuticals Announces Oral Presentations at the World Vaccine Congress
Published: 2023-03-27 (Crawled : 20:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M

Health Technology

| -95.56% | O: 3.02% H: 0.91% C: -5.82%
vaccine pharmaceuticals

Vaccine Vials Global Market Report to 2028: Sector to Reach $1 Billion by 2028 at a CAGR of 10.6%
Published: 2023-02-09 (Crawled : 20:00) - prnewswire.com
GLW M | $31.27 1.17% 0.0% 4.6M

Electronic Technology

| -11.49% | O: -0.6% H: 1.44% C: 1.32%
global report vaccine market

GeoVax Receives Notice of Allowance for Zika Vaccine Patent
Published: 2023-01-25 (Crawled : 20:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K

Health Technology

| 117.58% | O: -2.66% H: 104.41% C: 63.24%
patent vaccine

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate
Published: 2022-09-02 (Crawled : 20:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| Email alert Add to watchlist
covid-19 candidate global vaccine trial

European Commission Approves Purchase Agreement Amendment for Valneva’s Inactivated COVID-19 Vaccine
Published: 2022-07-20 (Crawled : 20:00) - biospace.com/
DVAX | $11.78 3.88% 3.74% 9.3M

Health Technology

| -22.06% | O: 0.41% H: 6.09% C: 3.7%
covid-19 vaccine agreement

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
Published: 2022-07-12 (Crawled : 20:00) - biospace.com/
AXIM | $0.0155 -6.67% 1.3M

Manufacturing

| -72.78% | O: 17.65% H: 0.0% C: -15.0%
covid-19 antibody vaccine axim study

COVID-19 Testing No Longer Required for Vaccinated Travelers
Published: 2022-03-08 (Crawled : 20:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M

Manufacturing

| -82.48% | O: 5.73% H: 0.0% C: 0.0%
covid-19 travel covid test vaccine

Javara Contributes to RSV Prevention Vaccine Trial in Collaboration with Privia Health and Moderna
Published: 2022-02-14 (Crawled : 20:00) - biospace.com/
PRVA | $18.08 1.46% 1.44% 990K

Manufacturing

| -24.97% | O: -0.38% H: 4.09% C: -2.53%
MRNA S | $101.44 -0.55% -0.55% 2.6M

Health Technology

| -35.88% | O: -2.35% H: 1.25% C: -9.56%
health trial collaboration vaccine

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.6894 -0.23% -0.23% 28K

Professional, Scientific, and T...

| -62.5% | O: 0.54% H: 7.03% C: -0.54%
al002 alzheimer fda system disease cel positive pons vaccine alzheimer’s alzheimer's disease alzheimer's

Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022
Published: 2021-12-27 (Crawled : 20:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M

Health Technology

| -58.62% | O: -2.8% H: 4.0% C: 1.6%
covid-19 covid switzerland vaccine

Vaccine & Flu Clinic
Published: 2021-12-22 (Crawled : 20:00) - taylordevices.com
TAYD A | $47.53 1.93% 1.89% 16K

Producer Manufacturing

| 367.06% | O: -1.22% H: 1.29% C: 1.29%
vaccine

Novavax Files NDA In Japan Following Phase III COVID Vaccine Trial Results
Published: 2021-12-17 (Crawled : 20:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M

Health Technology